Literature DB >> 20692722

Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation.

Samuel Bremmer1, Abby S Van Voorhees, Sylvia Hsu, Neil J Korman, Mark G Lebwohl, Melodie Young, Bruce F Bebo, Andrew Blauvelt.   

Abstract

An association between obesity and psoriasis has been reported. For a variety of reasons, obese persons with psoriasis are often more difficult to treat. We sought to review the literature on obesity and psoriasis and to discuss efficacy and safety data that could be utilized by clinicians who are making treatment decisions for obese persons with psoriasis. We performed a literature review using the terms "obesity and psoriasis" and "metabolic syndrome and psoriasis." Evidence from relevant literature was evaluated and categorized according to the criteria of Shekelle et al (published 1999). Numerous reports cite an association between obesity and psoriasis. When compared with non-obese patients with psoriasis, obese patients with psoriasis are more likely to experience certain adverse effects to medications and are less likely to respond favorably to systemic therapies. The amount of category I evidence for objectively determining the best treatment choices for obese patients with psoriasis was scarce and thus did not allow for the development of a treatment algorithm that could be generally applied for all psoriasis patients who are obese. Efficacy and safety concerns affected by obesity are important considerations for clinicians who are making decisions on proper treatment of psoriasis.
Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20692722     DOI: 10.1016/j.jaad.2009.09.053

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  16 in total

Review 1.  [Comorbidities and psoriasis. Impact on clinical practice].

Authors:  S Gerdes; U Mrowietz
Journal:  Hautarzt       Date:  2012-03       Impact factor: 0.751

Review 2.  Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations.

Authors:  Kerstin Wolk; Robert Sabat
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

3.  Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages.

Authors:  Martín Valdearcos; Esperanza Esquinas; Clara Meana; Lucía Peña; Luis Gil-de-Gómez; Jesús Balsinde; María A Balboa
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

4.  Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology.

Authors:  D J Drucker; C F Rosen
Journal:  Diabetologia       Date:  2011-09-03       Impact factor: 10.122

5.  The effect of weight loss surgery on the severity of psoriasis.

Authors:  E W Hossler; G C Wood; C D Still; C M Mowad; M S Maroon
Journal:  Br J Dermatol       Date:  2012-12-13       Impact factor: 9.302

6.  Optimal biologic dosing in management of obese patients with psoriasis.

Authors:  Shekhar Neema; Vikas Pathania; Niranjan Pudasaini; Radhakrishnan Subramaniyan
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

7.  Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis.

Authors:  B Truong; N Rich-Garg; B D Ehst; A A Deodhar; J H Ku; K Vakil-Gilani; A Danve; A Blauvelt
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-11-04

8.  The relation between visceral fat markers and cardiometabolic disease risks in psoriasis patients.

Authors:  Arzu Ataseven; Ruhusen Kutlu; Latife Uzun
Journal:  North Clin Istanb       Date:  2021-05-24

9.  Prevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years.

Authors:  Agnieszka B Owczarczyk-Saczonek; Roman J Nowicki
Journal:  Postepy Dermatol Alergol       Date:  2015-08-12       Impact factor: 1.837

10.  Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.

Authors:  Raphael Micheroli; Monika Hebeisen; Lukas M Wildi; Pascale Exer; Giorgio Tamborrini; Jürg Bernhard; Burkhard Möller; Pascal Zufferey; Michael J Nissen; Almut Scherer; Adrian Ciurea
Journal:  Arthritis Res Ther       Date:  2017-07-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.